|
| Genetic predisposition to multiple myeloma |
| |
| View Full Text View/Add Comment Download reader |
| DOI：10.46701/BG.2020012020103 |
| KeyWord:plasma cell malignancy, germline risk, racial and ethnic factors, GWAS |
| Author | Institution |
| Yan Cheng |
Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee 53226, WI, USA. |
| Fumou Sun |
Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee 53226, WI, USA |
| Xing Cui |
Department of Hematology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong 250014, China. |
| Siegfried Janz |
Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee 53226, WI, USA. |
|
| Hits: 2099 |
| Download times: 2345 |
| Abstract: |
| Genetic myeloma risk research relied on genome-wide association studies to identify 24 common but lowimpact germline predisposition alleles that account for an estimated one eighth of the heritable myeloma risk in
Caucasians. Next-generation sequencing, particularly whole-exome sequencing, uncovered a handful of rare but
high-impact myeloma risk loci that convey intriguing clues about etiology. The recent discovery of NCOA1 as a myeloma susceptibility gene in Han Chinese has set the stage for the more complete elucidation of the genetic myeloma risk across ethnic barriers. Validating individual myeloma risk loci at the functional level and integrating predisposition genes in genetic networks and biological pathways are important research tasks going forward. Candidate pathways that are currently emerging include plasma cell development, autophagy, telomere maintenance, and cell cycle regulation. An outstanding knowledge gap in the area of gene-environment interaction concerns the possibility that tumor-promoting effects of myeloma susceptibility alleles depend on specific environmental or occupational exposures. An implicit promise of myeloma risk research is the detection of new molecular targets for myeloma treatments and preventions. A related outcome is new biomarkers for patient stratification, prognostication, and development of individualized treatment plans. |
| Close |
|
|
|
